Professional Documents
Culture Documents
Gen. Surgeon
Benign Tumors
Papilloma
- intact basement membrane
- one end of malignant spectrum - follow
Inverted papilloma
- rare, usu. Dxed accidentaly
- resemble sebaceous cyst: smooth, pale, rounded
Hemangioma
- any size
- appear like collection of veins
- profuse bleeding, responds well to coagulation
Others:- nephrogenic adenoma, vesical leukoplacia,
pseudosarc. spindle cell nodule
Malignant Tumors
BLADDER CANCER
Epidemiology
Etiology
Etiology
* Genetics:
- activation of protoncogens (overexpression)
- inactivation of tumor suppressor genes eg. p53,pRb
interfers cell growth regulation tumor growth
* Viruses: HPV-16 &18
* Cyclophosphamide Rx:-9 fold, high-grade, invasive
Pathology
TCC:- >90%, CIS invasive disease
Invasive TCC (20%): 80% G3 poor prognosis
Superficial TCC (80%): G1-G2
Pathology
Spread
1. Lymphatic spread
- occur earlier independent of vascular spread
- pelvic LNs: paravesical (16%), obturator(74%),
external iliac(65%), parasacral(25%)
2. Vascular spread
- late event; liver(38%), lung(36%), bone(27%),
adrenal gland(21%), intestine(13%)
- bone, common esp. in bilhrzial SCC
Implantation:- traumatized site or wound eg. urethra,
abd. wound, prostatic fossa; (also intraop.)
- high-grade Tu
C/presentation
Adenocarcinoma 2%
- poor response to radiation & chemotherapy
Small cell carcinoma
Carcinosarcoma
Metastatic carcinoma
Neurofibroma
Pheochromocytoma
Primary lymphoma
Sarcomas:- eg. rhabdo-, liomyosarcoma
10
Clinical Prognostic
Indicators
(tumor recurrence & progression)
Grade & stage (depth of penetration)
Multifocality
Size > 5cm
Lymphatic invasion
Urothelial dysplasia or CIS near or other site
Papillary or solid Tu architecture
Frequency of prior Tu recurrence
* No imp. lab. parameter
11
Investigations
12
Management
= 70-80% superficial
= 5% metastatic
= 25% muscle invasion
= 25-30% limited to regional LNs
- any grade
Endoscopic Mx
Laser therapy
Photodynamic therapy
Cystectomy - failed above Rx
- high-grade T1
13
Management
Mx of Invasive
Urinary diversion
Mx of Invasive
Adjuncts to standard surgical therapy
(>stage T3)
17
Adjunct therapy
Neoadjuvant chemotherapy
- given before definitive local Rx
- test chemosensitivity & downstage
Adjuvant chemotherapy
- reduce local recurrence & distant metastatic
relapse objective response 70%, complete
response 15-20%, 2yr survival 15-20%
18
Partial cystectomy
- for Ca of urachus & diverticula
- not for TCC
19
Prognosis
5yr survival for TCC of bladder
Stage Surgery(%)
Ext. beam radiation(%)
T1
85-95
35
T2
75
40
T3
44
26
T4
16
12
Risk of progression of TCC
Grade
Risk (%)
G1
10-15
G2
14-37
20
G3
33-64
Prognosis
5yr survival M > F
- white > black (?invasive, late Dx, aggressive)
- mortality rate in elderly
====================================
=
The END
21